OpenAI 收购生物科技 AI 初创公司 Orchestra Bio
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI 于周二宣布收购成立四年的 AI 生物科技软件初创公司 Orchestra Bio，交易金额未披露，该公司截至 2025 年已融资约 2000 万美元，投资方包括 Andreessen Horowitz、Atria 和 8VC。Orchestra 开发的 AI 智能体帮助生物科技公司处理药物发现运营中的琐碎事务，从财务追踪到临床试验排期问题。OpenAI 表示将把 Orchestra 的团队和技术并入生命科学研究模型 Rosalind 及配套工具 Rosalind Workbench，Rosalind 的客户包括 Moderna 和 Novo Nordisk。
推荐理由
AI 评分 58
这笔收购显示头部 AI 实验室正把智能体能力延伸进药物研发运营环节，读者可据此观察实验室与垂直软件公司的关系变化。
主题
正文
当前显示原文，中文全文译文尚未就绪。
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind , its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma. In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors. In this case, Orchestra is getting absorbed, rather than stomped out.